Clinical Trial Update: Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 MORNINGSTAR trial evaluating mavrostobart (PT199), an anti-CD73 antibody, alone or with a PD-1 inhibitor or chemotherapy in non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Mavrostobart (PT199)

Snippet

Sponsor: Phanes Therapeutics | Conditions: Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING